Related Experiment Video
Updated: May 3, 2026
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous
Daniele De Filippis1, Annapina Russo1, Daniela De Stefano2
1Department of Pharmacy, University of Naples Federico II, Via D. Montesano, 49, 80131 Naples, Italy.
Abstract:
Chronic inflammation, a condition frequently associated with several pathologies, is characterized by angiogenic and fibrogenic responses that may account for the development of granulomatous tissue. We previously demonstrated that the chymase, rat mast cell protease-5 (rMCP-5), exhibits pro-inflammatory and pro-angiogenic properties in a model of chronic inflammation sustained by mast cells (MCs), granuloma induced by the subcutaneous carrageenan-soaked sponge implant in rat. In this study, we investigated the effects of palmitoylethanolamide (PEA), an anti-inflammatory and analgesic endogenous compound, on rMCP-5 mRNA expression and Microphtalmia-associated Transcription Factor (MITF) activation in the same model of chronic inflammation. The levels of rMCP-5 mRNA were detected using semi-quantitative RT-PCR; the protein expression of chymase and extracellular signal-regulated kinases (ERK) were analyzed by western blot; MITF/DNA binding activity and MITF phosphorylation were assessed by electrophoretic mobility shift assay (EMSA) and immunoprecipitation, respectively. The administration of PEA (200, 400 and 800 µg/ml) significantly decreased rMCP-5 mRNA and chymase protein expression induced by λ-carrageenan. These effects were associated with a significant decrease of MITF/DNA binding activity and phosphorylated MITF as well as phosphorylated ERK levels. In conclusion, our results, showing the ability of PEA to inhibit MITF activation and chymase expression in granulomatous tissue, may yield new insights into the understanding of the signaling pathways leading to MITF activation controlled by PEA.
Insights
Palmitoylethanolamide (PEA) reduces chronic inflammation by decreasing rat mast cell protease-5 (rMCP-5) and inhibiting Microphtalmia-associated Transcription Factor (MITF) activation. This study reveals PEA
Area of Science:
- Inflammation and Immunology
- Molecular Biology
- Pharmacology
Background:
- Chronic inflammation involves angiogenic and fibrogenic responses, leading to granulomatous tissue formation.
- Rat mast cell protease-5 (rMCP-5) exhibits pro-inflammatory and pro-angiogenic properties in chronic inflammation models.
- Mast cells (MCs) play a crucial role in sustaining chronic inflammatory conditions.
Purpose of the Study:
- To investigate the effects of palmitoylethanolamide (PEA) on rMCP-5 mRNA expression and MITF activation in a rat granuloma model.
- To explore the potential of PEA as a therapeutic agent for chronic inflammatory conditions.
Main Methods:
- Induction of chronic inflammation using a carrageenan-soaked sponge implant in rats.
- Semi-quantitative RT-PCR to detect rMCP-5 mRNA levels.
- Western blot for chymase and ERK protein expression.
- Electrophoretic mobility shift assay (EMSA) for MITF/DNA binding activity.
- Immunoprecipitation for MITF phosphorylation.
Main Results:
- PEA administration significantly decreased rMCP-5 mRNA and chymase protein expression induced by lambda-carrageenan.
- PEA treatment led to a significant reduction in MITF/DNA binding activity and phosphorylated MITF levels.
- Phosphorylated ERK levels were also significantly decreased following PEA administration.
Conclusions:
- Palmitoylethanolamide (PEA) effectively inhibits MITF activation and chymase expression in granulomatous tissue.
- PEA demonstrates potential in modulating key signaling pathways involved in chronic inflammation.
- These findings offer new insights into the therapeutic mechanisms of PEA in inflammatory diseases.
